McKenzie, Dr Leanne S Md

Brain Cancer Canada Funds $68,000 for Innovative DIPG Vaccine Clinical Trial

- Brain Cancer Canada has awarded $68,000 to researchers at the University of Calgary and Alberta Children's Hospital for a clinical trial of a neoantigen-based anti-cancer vaccine targeting DIPG, the most aggressive form of pediatric brain cancer. - The research, led by Dr. Aru Narendran and Dr. Patrick Sipila, aims to train patients' immune systems to recognize and eliminate tumor cells, potentially offering new hope for a disease with fewer than 10% of children surviving two years post-diagnosis. - The announcement coincides with DIPG Awareness Day, with landmarks across Canada illuminated in yellow to raise awareness for this devastating pediatric brain cancer that has seen little improvement in survival rates despite decades of cancer research advances.